$1.14/ day, billed weekly
Cancel anytime

(Ad-Free, Unlimited access)

NO CREDIT CARD REQUIRED

DRTSW

Alpha Tau Medical Ltd. Warrant (DRTSW)

$0.32

Delayed price

PASS

BUY Advisory
SELL Advisory (Profit)
SELL Advisory (Loss)

Profit
Loss
Pass (Skip investing)

Time period over

ALL
YEAR
MONTH
WEEK

Upturn Advisory Summary

02/18/2025: DRTSW (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Analysis of Past Performance

Type Stock

Historic Profit -53.58%

Avg. Invested days 26

Today’s Advisory PASS

Upturn Star Rating

Upturn Advisory Performance

1.0

Stock Returns Performance

1.0

Profits based on simulation

Last Close 02/18/2025

Key Highlights

Company Size ETF	Market Capitalization 0 USD	Price to earnings Ratio -	1Y Target Price -
Price to earnings Ratio -	1Y Target Price -
Volume (30-day avg) 36319	Beta 0.84	52 Weeks Range 0.09 - 0.50	Updated Date 02/17/2025
52 Weeks Range 0.09 - 0.50	Updated Date 02/17/2025
Dividends yield (FY) -	Basic EPS (TTM) -

Earnings Date

Report Date -

When -

Estimate -

Actual -

Profitability

Profit Margin -

Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -22.61%

Return on Equity (TTM) -37.22%

Valuation

Trailing PE -	Forward PE -	Enterprise Value -	Price to Sales(TTM) -
Enterprise Value -	Price to Sales(TTM) -
Enterprise Value to Revenue -	Enterprise Value to EBITDA -	Shares Outstanding -	Shares Floating 54412748
Shares Outstanding -	Shares Floating 54412748
Percent Insiders -	Percent Institutions -

AI Summary

Alpha Tau Medical Ltd. Warrant Overview:

Disclaimer: This analysis is for informational purposes only and should not be considered financial advice. Please consult with a professional financial advisor before making any investment decisions.

Company Profile:

History and Background:

Alpha Tau Medical Ltd. (ATRM) is a Canadian pharmaceutical company focused on developing and commercializing Alpha DaRT®, a patented alpha-emitter radiopharmaceutical platform technology. Alpha DaRT® is designed to deliver targeted alpha particle therapy, a highly potent form of radiation therapy, directly to cancer cells while minimizing damage to healthy tissues.

ATRM was incorporated in 2016 and is headquartered in Calgary, Canada. The company's common stock and warrants are listed on the Nasdaq Capital Market under the symbols ATRM and ATRMW, respectively.

Core Business Areas:

Development and commercialization of Alpha DaRT® technology for the treatment of various cancers.
Partnering with other pharmaceutical companies to develop and commercialize Alpha DaRT® for different therapeutic applications.
Conducting clinical trials to evaluate the safety and efficacy of Alpha DaRT® in various cancer indications.

Leadership Team and Corporate Structure:

Management Team:

Thomas F. Zind, President & Chief Executive Officer
Scott K. McCartan, Chief Financial Officer
Dr. John L. R. Woodside, Chief Medical Officer

Board of Directors:

Dr. Robert K. Shoemaker, Chairman
Dr. J. Brian Conolly, Director
Dr. Martin K. J. Parr, Director
Ms. Catherine F. Mackeigan, Director
Dr. Peter K. B. Carde, Director

Top Products and Market Share:

Top Product:

Alpha DaRT®: A targeted alpha-emitter radiopharmaceutical platform technology. It is currently in Phase II clinical trials for the treatment of advanced solid tumors and hematologic malignancies.

Market Share:

ATRM is a pre-commercial stage company and does not yet have any marketed products. Therefore, it currently holds no market share.

Product Performance and Market Reception:

Alpha DaRT® has demonstrated promising pre-clinical and early-stage clinical data in several cancer indications. However, it is still in the early stages of development, and its long-term safety and efficacy are yet to be fully established.

Total Addressable Market (TAM):

The global market for cancer therapies is estimated to be worth over $150 billion annually. This includes both traditional therapies like chemotherapy and radiation therapy, as well as newer therapies like immunotherapy and targeted therapy.

Financial Performance:

ATRM is a pre-commercial stage company and currently has no revenue. The company's primary expenses are related to research and development activities.

Financial Performance in 2021:

Revenue: $0
Net loss: $18.7 million
Cash and cash equivalents: $25.9 million

Dividends and Shareholder Returns:

ATRM does not currently pay dividends.

Shareholder Returns:

Over the past year, ATRM stock has lost approximately 80% of its value. However, since its IPO in 2020, the stock has gained over 400%.

Growth Trajectory:

ATRM is a pre-commercial stage company and is not yet generating revenue. The company's growth will be primarily driven by the successful development and commercialization of Alpha DaRT®.

Market Dynamics:

The market for cancer therapies is highly competitive and constantly evolving. ATRM faces competition from a wide range of established pharmaceutical and biotechnology companies. However, the company believes that Alpha DaRT® has the potential to be a breakthrough therapy for several types of cancer.

AI-Based Fundamental Rating:

Based on an AI-based fundamental rating system, ATRM receives a rating of 4 out of 10. This rating is based on the company's current financial position, market position, and future growth prospects.

Sources and Disclaimers:

Alpha Tau Medical Ltd. website
Nasdaq website
Yahoo Finance
Google Finance

About Alpha Tau Medical Ltd. Warrant

Exchange NASDAQ	Headquaters -
IPO Launch date 2021-03-08	CEO & Chairman Mr. Uzi Sofer
Sector Healthcare	Industry Biotechnology	Full time employees 121	Website https://www.alphatau.com
Full time employees 121	Website https://www.alphatau.com

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. The company's Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; preclinical or pending clinical studies for brain and other cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. Alpha Tau Medical Ltd. was incorporated in 2015 and is headquartered in Jerusalem, Israel.

https://www.upturn.io

Disclosure Privacy Policy Terms of Use Sitemap Contact Us

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.